(Q33375169)

26 July 2017

title

A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours (English)

1 reference

26 July 2017

1 reference

M Rasschaert

1

1 reference

26 July 2017

D Schrijvers

2

1 reference

26 July 2017

J Van den Brande

3

1 reference

26 July 2017

J Dyck

4

1 reference

26 July 2017

J Bosmans

5

1 reference

26 July 2017

K Merkle

6

1 reference

26 July 2017

J B Vermorken

7

1 reference

26 July 2017

language of work or name

English

0 references

publication date

8 May 2007

1 reference

British Journal of Cancer

26 July 2017

published in

1 reference

26 July 2017

volume

96

1 reference

26 July 2017

issue

11

1 reference

26 July 2017

page(s)

1692-1698

1 reference

A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359912

Phase II trial of second-line bendamustine chemotherapy in relapsed small cell lung cancer patients

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359912

Characterization of two phase I metabolites of bendamustine in human liver microsomes and in cancer patients treated with bendamustine hydrochloride

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359912

The relationship between shear stress and flow-mediated dilatation: implications for the assessment of endothelial function

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359912

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359912

Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359912

Phase I studies with bendamustine: an update

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359912

Metabolism and mechanisms of action of bendamustine: rationales for combination therapies

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359912

In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359912

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359912

Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359912

Repeated administration of short infusions of bendamustine: a phase I study in patients with advanced progressive solid tumours

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359912

Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359912

Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359912

Toxicity of the alkylating agent bendamustin

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359912

High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas

14 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603776

Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase acti

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603776

Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603776

Aminos�ureantagonisten. III. ?-[Bis-(?-chlor�thyl)-amino-benzimidazolyl-(2)]-propion- bzw. -butters�uren als potentielle Cytostatika

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603776

Synthesis and characterization of some new phase II metabolites of the alkylator bendamustine and their identification in human bile, urine, and plasma from patients with cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6603776

Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and predniso

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359912

Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359912

Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19).

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359912

In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359912

Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359912

Regression of brain metastases from breast carcinoma after chemotherapy with bendamustine.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359912

Selective uptake of the anticancer drug bendamustine by liver and kidney tissues following its intravenous administration to mice.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2359912

[Pharmacokinetics of bendamustin (Cytostasan) in B6D2F1-mice]

31 October 2018

1 reference

12 December 2020

Hepatobiliary elimination of bendamustin (Cytostasan) in rats

1 reference

12 December 2020

[Chemotherapy of advanced non-small-cell and small-cell bronchial carcinoma with bendamustine--a phase II study]

1 reference

12 December 2020

Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and

1 reference

12 December 2020

Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6603776

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference